Over half of Medicaid enrollees still do not know work requirements are coming. A Health Management Academy survey found 55 percent unaware, and 85 percent unaware that eligibility redeterminations shift from twelve months to six. The Urban Institute projects 3 to 7 million people will lose expansion coverage by 2028 from work requirements alone, with another 2 to 3.1 million lost to more frequent verification. Awareness, not employment, will drive most of the coverage loss, so advocacy organizations need enrollee-education campaigns in market now, not federal talking points in the fall.

A Georgetown study found 2 million children dropped off Medicaid and CHIP since January 2025, pushing the child uninsured rate from 4.6 percent to 5.7 percent. Every child who loses coverage becomes a delayed diagnosis and a harder, costlier case later. Commercial teams building pediatric access programs should treat this enrollment cliff as a market signal, not a policy footnote.

Forty-eight patient organizations warned that the final work reporting requirement rule will trigger massive coverage losses. Patient groups rarely align in these numbers, and when they do, payers and manufacturers should read it as a coalition, not a press release. The advocacy community drew a clear line, and brands that ignore it will end up defending the wrong side of it in front of their own patients.

A federal watchdog found UnitedHealth, Humana, and CVS denied more than 70 percent of long-term care hospital requests and over half of inpatient rehab requests, far above smaller insurers. A separate OIG report showed UnitedHealth restricting rehab care with undisclosed internal criteria that went beyond Medicare rules, and the insurer overturned 99.7 percent of the skilled nursing appeals it received. Denials a plan reverses on appeal were never clinical decisions, they were administrative gatekeeping. Market access leaders should map where these denials concentrate, because that is exactly where patients need a partner.

CMS proposed a 2.4 percent Medicare outpatient pay bump for 2027 and paired it with another 340B payment overhaul. The pairing signals that federal pressure on the drug discount program will keep building through the next rule cycle. Manufacturers and hospitals both need a 340B strategy that survives the next rule, not just this one.

The FDA authorized Colorado's Section 804 program, the first working state-level drug importation pathway from Canada. The approval hands every other state a template and directly challenges the domestic pricing structure the industry has defended for decades. Manufacturers should model importation as a real access channel now, because this political win will travel.

A new OMB rule rewrote the uniform guidance governing federal research grants, adding criteria that let political priorities override scientific merit. Research leaders warn it will push top scientists abroad and erode the biomedical pipeline that becomes tomorrow's therapies. Companies that depend on federally funded science should treat research-funding volatility as a pipeline risk, not a Washington story.

Tufts researchers reported 340B sales grew from 9 billion dollars a decade ago to 82 billion in 2024, shifting billions in discounts away from employers, health plans, and Medicaid. More than 5 billion dollars in commercial rebates vanished in 2024 alone, and duplicative-discount rules push those costs straight into premiums. When a program built for safety-net patients funds hospital expansion instead, patients pay twice, once at the pharmacy and again at open enrollment.

Eli Lilly cut off 340B discounts to hospitals that would not submit claims-level data, joining a growing list of manufacturers rewriting the rules of engagement. The move squeezes safety-net hospitals that rely on 340B margins to fund care for underserved communities. Manufacturers gain leverage, hospitals lose it, and patients sit in the middle of a fight neither side frames around them, so advocacy organizations should demand that any 340B savings map to documented patient benefit.

The ADAP Advocacy Association detailed how private equity became an access barrier, with 488 PE-owned hospitals now operating and acquisitions reaching 79 billion dollars in a single peak year. Emergency physician salaries fell 18.2 percent after acquisition while Medicare claims rose 30.5 percent, and Quorum Health converted four rural hospitals to nonprofit status specifically to capture 340B pricing. When ownership optimizes for extraction, patients feel it in longer waits and thinner staffing.

Elevance returned 342 million dollars to CMS after the agency threatened to suspend Medicare Advantage enrollment over years of improper diagnosis-code billing, and it submitted corrections on encrypted flash drives rather than the required electronic reporting. The refund fits a systemic overpayment pattern that OIG has flagged across the sector. Taxpayers and patients funded that gap the whole time, and the clawback recovered only a fraction of the estimated billion-dollar exposure.

Hospital prices rose 5.7 percent year over year while physician fees rose 2.8 percent and drug prices fell 2.1 percent, and national health spending will top 6 trillion dollars in 2026 on a 7.3 percent jump. Hospitals, not drugs, drive the inflation curve, yet the pricing debate keeps pointing at pharma. Commercial teams should bring that data to every value conversation, because the patient absorbing the premium increase deserves an honest account of where the money goes.

The PBM lobby launched the biggest advertising campaign in its history, doubling federal lobbying to roughly 18 million dollars in 2024, while the FTC sued the three largest PBMs over insulin price inflation. Express Scripts settled, and bipartisan PBM reform advanced in states from West Virginia to Minnesota. A lobbying blitz this size signals a business model under existential pressure, and advocacy organizations should press the transparency case while the political will exists.

A May 2026 Morning Consult survey found 47 percent of Americans blame corporate insurers first for rising costs, even as national spending hit 5.3 trillion dollars and 18 percent of GDP. When nearly half the public names one villain, reputation risk becomes business risk. Brands that visibly align with patients now hold an advantage they did not have to manufacture, and brands that stay silent inherit the blame by default.

The American Diabetes Association deployed private security to remove members handing out a Diabetes Care editorial critical of NIH funding cuts, then defended the move as two leaders resigned and nearly 6,000 people signed an open letter demanding accountability. A patient organization that silences its own clinical community forfeits the credibility that makes advocacy work. The episode is a warning for every disease group about the difference between managing a message and serving a mission.

ProPublica launched Claim File Helper, a free tool that forces insurers to hand over the claim file behind a denial within 30 days, arriving the same month that Cigna denied Keaton Herzer, 35, a targeted cancer therapy and a liver transplant his MD Anderson and Houston Methodist physicians called life-saving. One denial becomes a headline, and thousands more never do. When advocates hand patients real leverage, the power balance shifts one appeal at a time, and commercial teams should fund the tools and navigation that turn a denial into an overturned decision.

UnitedHealthcare opened its headquarters to journalists and influencers in a no-news event built to reset sentiment after a brutal year, while executives dismissed a wave of lawsuits as commercial disagreements. A campaign cannot outrun a denial rate, and patients judge the record, not the tour. Reputation follows behavior, and the fastest way to rebuild trust is to stop generating the denials that broke it.

Courier Health's 2026 State of Patient-Centricity found 83 percent of teams now use AI, up from 46.6 percent, but only 12 percent run approved tools with governance and 46 percent still work from siloed data. Patient-centricity without clean data and governance stays a slogan, and patients can tell the difference between a program and a press release. Teams that fix the data foundation first will turn the patient-centricity language into measurable outcomes.

Anthropic released Claude Science, aimed at researchers and biopharma, with CEO Dario Amodei projecting impact on par with what Claude Code did for software development. Research teams that adopt early will compress timelines their competitors still treat as fixed. Faster science helps patients only when access keeps pace, so build the access plan alongside the pipeline, not after it.

Astellas deployed AI across global clinical operations, internalizing translation, protocol development, and patient outreach, cutting most CRO work and saving roughly 406 million dollars over two years while posting record 2025 revenue. It pushed its KRAS-targeting degrader into phase 3 for pancreatic cancer, one of the hardest tumors to treat. Efficiency that funds harder science serves patients only if the savings reach the people waiting for the therapy, so tie the operational win to an access commitment.

Doctronic released results from its Utah AI prescribing pilot, showing the system managed refills for common conditions with accuracy that matched physician decisions in controlled study. Automated prescribing could widen access where clinicians run short, or it could scale error if governance lags. Deploy it where it closes access gaps for patients, and prove the safety before the scale.

Natera's Signatera builds a personalized test for each patient's tumor DNA, detecting recurrence more sensitively than scans, and a bladder cancer trial showed test-negative patients reached 100 percent one-year and 97 percent two-year survival without added therapy. More than half of oncologists have ordered it, but most have not made it routine, and coverage still trails the evidence. Advocacy and commercial teams in oncology should push payers to cover MRD testing where the data supports it, because earlier certainty spares patients both toxicity and fear.

The FDA agreed to reconsider Regenxbio's gene therapy for Hunter syndrome after new clinical data followed an initial rejection, and a parallel FDA pilot aims to speed early-stage trials for rare diseases and unmet need. Hunter syndrome affects roughly 1 in 100,000 to 170,000 males and offers patients few options today. When the agency shows it will follow strong data, rare-disease families gain the flexibility they need to survive the review process, so sponsors should engage advocacy communities early to keep patient priorities in the trial design.

Take the free Advocacy Influence Diagnostic at aid.elavay.com to benchmark your advocacy function and get a real understanding of its impact within your organization.

Find every source cited in this brief, and the other articles our CEO, Matt Toresco, found valuable last month, at intelligence.archo.io.

For ELAVAY Intelligence briefings and Archo's syndicated research on how patient advocacy organizations evaluate pharma and biotech companies, email [email protected].

The ELAVAY report is now available. To request the findings or schedule a briefing, email Archo at [email protected].

For commercial training programs and advocacy strategy consulting, reach Matt directly at [email protected].

Connect with the advocacy community at wethepatients.org and advocatebridge.org.